Xizang Weixinkang Pharmaceutical

Xizang Weixinkang Pharmaceutical

Xizang Weixinkang Pharmaceutical was founded in 2002 by Zhang Yong and is headquartered in Lhasa, with an additional R&D center in Beijing. The company listed on the Shanghai Stock Exchange and focuses on the research, development, production, and sales of pharmaceutical products for the Chinese market. Its operational base in the Xizang Autonomous Region gives it a distinct regulatory and economic posture compared to coastal Chinese pharma firms. The company pursues a dual strategy of in-house development and in-licensing. Its most prominent known partnership is the exclusive licensing agreement for Maxigesic IV — an intravenous paracetamol-ibuprofen combination — secured through agreements with AFT Pharmaceuticals and Hyloris Pharmaceuticals. This deal aims to bring a differentiated hospital pain-management product to the Chinese market. Beyond in-licensing, the firm engages in formulation R&D at its Beijing facility and maintains an intellectual property portfolio in China. The geographic focus remains exclusively China, targeting domestic hospital and commercial channels. Weixinkang operates with Zhang Yong as Chairman and Director, supported by Liu Weiqiang as General Manager and Yu Haibo as Board Secretary. The corporate structure integrates pharmaceutical operations with a strategic investment function — functioning effectively as an asset owner that deploys its balance sheet into drug licensing, development partnerships, and commercialization rights. No recent operational event from the last 24 months is verifiable from available public records. The firm's structural distinction lies in its use of a public-company balance sheet as a corporate venture platform for in-licensing deals. Unlike pure venture firms or typical corporate VCs that take equity, Weixinkang acquires territorial commercialization rights directly — a capital-allocation model that blends operating-company P&L with pharmaceutical asset investing.